Skip to main content
Fig. 5 | Pediatric Rheumatology

Fig. 5

From: Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE

Fig. 5

Treatment choices for renal flare in proliferative LN after achieving remission with MMF induction therapy. Sixty-one nephrologists and thirty-three rheumatologists responded to survey question. Treatment choices are depicted in graph. Statistical analysis of differences in responses between groups is depicted in table. P value < 0.05 is considered statistically significant. (RTX = Rituximab, CNI = Calcineurin Inhibitor, MMF = Mycophenolate mofetil, CYC = Cyclophosphamide)

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096